AbbVie Inc.

Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies (2025) Atreya R, Ferrante M, Panaccione R, Feagan B, Shchukina O, Jairath V, Rieder F, et al. Journal article A Warm Welcome to MedChem: The Frontiers in Medicinal Chemistry 2025 (2025) Schiedel M, Pinto M, Unzue Lopez A, Barbie P, Pape F, Tarasewicz A, Hessler G, et al. Journal article Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials (2024) Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, et al. Journal article Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease (2024) Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D’Haens G, Ferrante M, Schreiber S, et al. Journal article Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy (2024) Colombel JF, Hisamatsu T, Atreya R, Bresso F, Thin L, Panaccione R, Parra RS, et al. Journal article Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure (2024) Peyrin-Biroulet L, Panaccione R, Louis E, Atreya R, Rubin DT, Lindsay JO, Siffledeen J, et al. Journal article Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study. (2024) Kaeley GS, Schett G, Conaghan PG, McGonagle D, Behrens F, Goupille P, Gaillez C, et al. Journal article Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice (2023) Werner SG, Baraliakos X, Reckert S, Bohl-Bühler M, Laliberté MC, Girard T, Jeromin K, et al. Journal article Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study (2020) Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, et al. Journal article A TNM-Immune (TNM-I) classification staging system for predicting survival in colon cancer in a multicenter international SITC study (2020) Mlecnik B, Bifulco C, Marliot F, Lugli A, Nagtegaal I, Hartmann A, Van Den Eynde M, et al. Conference contribution